Epidermolysis Bullosa Therapeutics Market Report Analysis, Global Size, Share, Industry Growth, Business Insight, Demand, Regional Analysis, Top Company Profile, Strategy Profiling, Challenges, Key Findings 2026
SEATTLE, April 12, 2021, (PHARMIWEB) — Global Epidermolysis Bullosa (EB) Therapeutics Market
Epidermolysis Bullosa (EB) is a rare, genetic disorder of skin tissues. People suffering from EB have fragile skin, which is susceptible to blisters leading to wounds that are difficult to heal. Symptoms related to this disorder includes, blistering of skin, deformity or loss of fingernails and toenails, internal blistering including on the throat, esophagus, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring, and hair loss (scarring alopecia).
*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2214
Global Epidermolysis Bullosa Therapeutics Market Insights
Development of various pipeline drugs for the treatment of EB is a major factor expected to drive the global EB therapeutics market development. For instance, Fibrocell Technologies, Inc. is undergoing a clinical trial for its drug FCX-007, for the treatment of EB. This drug is under clinical phase II, which is scheduled to be completed by December 2023. Moreover, TWi Biotechnology, Inc. is conducting the phase II clinical trial for the drug AC-203 to treat skin lesions in EB and is expected to complete the study in February 2019. Furthermore, Amryt Research Limited is conducting clinical trial phase III for its drug Oleogel-S10, which is intended for the treatment of wounds in EB. The trial is slated to be completed by September 2020.
In May 2018, Abeona Therapeutics Inc. announced updated clinical data from the Phase I/II trial of EB-101, a gene-corrected skin graft cell therapy for patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). The EB-101 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in January 2018, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2017. Therefore, a large number of drugs currently in the pipeline is projected to provide innumerable growth opportunities for the players in the global epidermolysis bullosa therapeutics market during the forecast timeline.
Global Epidermolysis Bullosa Therapeutics Market Restraints
Withdrawal of drugs failing to meet expectations is expected to restrain growth of EB therapeutics market. For instance, in September 2017, Rival Amicus Therapeutics, withdrew its AP101 drug which was in phase III clinical study. AP101 drug was a water based cream, which is only supposed to be applied when dressings are changed every three or four days, as recommended for EB patients. Such water-based cream required patients to change dressings daily and the company indicated this might be the reason for its failure to hit targets for wound closure in patients within three months.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2214
Global Epidermolysis Bullosa Therapeutics Market – Regional Analysis
The North America region is expected to witness considerable growth in the global EB therapeutics market, due to the effective inorganic growth strategies adopted by the key market players. For instance, in August 2015, Amicus Therapeutics, a biotechnology company involved in developing drugs for orphan diseases acquired Scioderm, Inc., a company involved in developing innovative therapies for treating diseases. This acquisition aims to accelerate clinical development of Zorblisa, drug of Amicus Therapeutics, which is under preclinical investigation for commercialization, for the treatment of epidermolysis bullosa.
Strategies used by the key players in the Asia Pacific region is also expected to drive the growth of the EB therapeutics market in the region. For instance, in August 2018, RegeneRx Biopharmaceuticals, Inc., entered into a joint venture with YuYang DNU, a Korean company to develop its product- RGN-137 on a global basis for the orphan indication, epidermolysis bullosa (EB) which is under preclinical study. Furthermore, YuYang will invest about US$17.8 million in cash for its clinical development.
The leading players operating in the global epidermolysis bullosa therapeutics market include Birken AG, Fibrocell Science, Inc., RegeneRx Biopharmaceuticals, Inc., GlaxoSmithKline Plc., InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., Scioderm, Inc., Stratatech Corporation, TWi Biotechnology Inc., Amryt Research Limited, and WAVE Life Sciences Ltd.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/epidermolysis-bullosa-therapeutics-market-2214
By Drug Type,
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire